Pfizer Inc. operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Pfizer Inc. with three other
companies in this sector in the United States:
sales of $41.24 billion
of which 83%
Roche Holding Aktiengesellschaft
of which 77%
was Pharmaceuticals), and
of which 66%
was Innovative Medicines).
During the year ended December of 2017, sales at
Pfizer Inc. were $52.55 billion.
decrease of 0.5%
versus 2016, when the company's sales were $52.82 billion.
Contributing to the drop in overall sales was the 10.6% decline
in Essential Health, from $23.63 billion to $21.12 billion.
However, these declines were partially offset by the increase in sales of
Operating Segment-Global Innovative Phar (up 7.6% to $31.42 billion)